# US 2024/0123083 A1 · Hybrid aav-anellovectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0123083 A1
- Document ID: US20240123083A1
- Status: Published application
- Kind: A1
- Application number: 18/264,320
- Filed: 2022-02-07
- Published: 2024-04-18
- Earliest claimed: 2021-02-08
- Assignees: Flagship Pioneering Innovations V, Inc.
- Applicants: Flagship Pioneering Innovations V, Inc.
- Inventors: Simon Delagrave; Kevin James Lebo; Michael James DiBiasio-White; Dhananjay Maniklal Nawandar
- Web page: https://patentgrep.com/patent/US20240123083A1

## CPC

- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- C07K 14/005: from viruses
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 2750/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/00043: viral genome or elements thereof as genetic vector
- C12N 2750/00044: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14144: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention relates generally to compositions for making and administering anellovectors and uses thereof.

## Claims

### Claim 1

A viral particle comprising a circular DNA comprising (i) an AAV origin of replication, (ii) a promoter operably linked to a sequence encoding a therapeutic RNA or polypeptide, and (iii) a sequence that binds an Anellovirus ORF1 molecule, the circular DNA being encapsidated by a capsid comprising an Anellovirus ORF1 molecule.

### Claim 2

A vector comprising:
a) a proteinaceous exterior comprising an Anellovirus ORF1 molecule; and
b) a genetic element comprising a non-Anellovirus origin of replication;
optionally wherein the genetic element further comprises: (i) a nucleic acid sequence encoding an exogenous effector, and/or (ii) a promoter element operatively linked to the nucleic acid sequence encoding the exogenous effector.

### Claim 3

A genetic element comprising:
a protein binding sequence that specifically binds an Anellovirus ORF1 molecule (e.g., a 5′ UTR); and
an AAV origin of replication, e.g., comprised in a first AAV inverted terminal repeat (ITR);
optionally, a nucleic acid sequence encoding an exogenous effector (e.g., a therapeutic exogenous effector); and
optionally, a promoter element operatively linked to the nucleic acid sequence encoding the exogenous effector.

### Claim 4

A system comprising:
a) a first nucleic acid, wherein the first nucleic acid is a genetic element or a genetic element construct, the first nucleic acid comprising:
an AAV origin of replication, e.g., comprised in a first AAV inverted terminal repeat (ITR);
optionally, a nucleic acid sequence encoding an exogenous effector (e.g., a therapeutic exogenous effector); and
optionally, a promoter element operatively linked to the nucleic acid sequence encoding the exogenous effector;
b) a second nucleic acid encoding an Anellovirus ORF1 molecule.

### Claim 5 (depends on 2)

A method of delivering an exogenous effector to a target cell (e.g., a vertebrate cell, e.g., a mammalian cell, e.g., a human cell), the method comprising introducing into the cell a vector of claim 2.

### Claim 6 (depends on 2)

A method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising introducing into the subject a vector of claim 2.

### Claim 7

A method of making a therapeutic composition, comprising:
(a) providing one or a plurality of host cells comprising exogenous DNA comprising
(i) an AAV origin of replication,
(ii) a promoter operably linked to a sequence encoding a therapeutic effector (e.g., a therapeutic RNA or polypeptide),
(iii) a sequence encoding an Anellovirus ORF1 molecule,
(iv) optionally a sequence encoding an Anellovirus ORF2 molecule,
(v) optionally a sequence encoding an AAV REP2 sequence
(vi) optionally a sequence encoding one or a plurality of helper proteins, e.g., an Adenovirus helper protein, e.g., an E2A molecule, an Adenovirus E4 molecule, and/or an Adenovirus VARNA molecule;
(b) culturing the one or plurality of host cells under conditions suitable for formation of vectors (e.g., anellovectors, e.g., viral particles) comprising a proteinaceous exterior (e.g., capsid) comprising a sufficient number of the ORF1 molecules to enclose (e.g., encapsidate) the genetic element;
(c) purifying the vectors produced in step (b) from the cell culture,
thereby making a therapeutic composition.
